Hans Rolando Zamora-Obando
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hans Rolando Zamora-Obando has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Aline Cristina Dias
Laboratory of Analysis of Biomolecules Tiselius, Department of Analytical Chemistry, Institute of Chemistry, Universidade Estadual de Campinas (UNICAMP), São Paulo, Brazil
3 shared publications - Ana Valéria Colnaghi Simionato
Laboratory of Analysis of Biomolecules Tiselius, Institute of Chemistry, Universidade Estadual de Campinas (UNICAMP), Campinas, Brazil
3 shared publications - André Luiz Melo Camelo
Laboratory of Analysis of Biomolecules Tiselius, Department of Analytical Chemistry, Institute of Chemistry, Universidade Estadual de Campinas (UNICAMP), São Paulo, Brazil
3 shared publications - Alberto Azoubel Antunes
Department of Surgery, Division of Urology, Faculdade de Medicina, Universidade de São Paulo, São Paulo 01246-903, SP, Brazil
2 shared publications - André Matos de Oliveira
Division of Urology, School of Medicine, University of São Paulo, São Paulo, São Paulo, Brazil
2 shared publications - João Pedro Simon Farah
Department of Fundamental Chemistry, Institute of Chemistry, University of São Paulo, São Paulo, Brazil
2 shared publications
Latest Publications
- Open Access
- 1 November 2025
- Published by Springer Nature in Metabolomics
- Vol. 21 (6) , 1
Correction: Self-organizing maps to aid prognostic and diagnostic biomarker identification in exploratory metabolomics of benign prostatic hyperplasia
- 1 November 2025
- Published by Springer Nature in Metabolomics
- Vol. 21 (6) , 1
Open AccessCorrection: Self-organizing maps to aid prognostic and diagnostic biomarker identification in exploratory metabolomics of benign prostatic hyperplasia
- 19 June 2025
- Published by Springer Nature in Metabolomics
- Vol. 21 (4) , 83
Self-organizing maps to aid prognostic and diagnostic biomarker identification in exploratory metabolomics of benign prostatic hyperplasia
Population aging is increasing rapidly, representing a global trend that has launched many discussions regarding older adult's quality of life. Benign prostatic hyperplasia (BPH) is a commonly found condition among older men, affecting the lower urinary tract and quality of life. BPH diagnosis typically involves clinical evaluations which cannot accurately identify patients who will develop a clinically significant disease in the future. Metabolomics emerges as a promising approach to understand the metabolic pathways associated with BPH, offering potential aid in early diagnosis. To investigate the metabolic profile of BPH patients compared with a control group for diagnosing BPH at different stages. A total of 62 individuals were selected and divided into two groups: 32 BPH (prostate volume > 40 mL) and 30 healthy individuals (prostate volume ≤ 40 mL and normal voiding patterns). Plasma samples were analyzed by LC-HRMS. Data were processed using unsupervised and supervised techniques. Self-organizing maps were further used to aid in the identification of potential biomarkers. Self-organizing maps revealed three distinct groups which expanded upon the existing groups indicated by the medical team. Discriminant analysis models showed good predictive ability and accuracy, providing a classification perspective of patients and expanding diagnostic possibilities for different health states. Integration of chemical data with clinical variables revealed meaningful correlations. Our results also suggest the presence of discriminatory metabolites related to inflammation and oxidation processes, clarifying the metabolic basis of BPH. Self-organizing maps proved their effectiveness in classifying groups of samples from BPH patients, revealing potential biomarkers that went undetected by conventional data analysis methods. This approach underscores metabolomics as a relevant tool in identifying hidden patterns and supporting the development of more robust diagnostic and prognostic models.
- 19 June 2025
- Published by Springer Nature in Metabolomics
- Vol. 21 (4) , 83
Self-organizing maps to aid prognostic and diagnostic biomarker identification in exploratory metabolomics of benign prostatic hyperplasia
Population aging is increasing rapidly, representing a global trend that has launched many discussions regarding older adult's quality of life. Benign prostatic hyperplasia (BPH) is a commonly found condition among older men, affecting the lower urinary tract and quality of life. BPH diagnosis typically involves clinical evaluations which cannot accurately identify patients who will develop a clinically significant disease in the future. Metabolomics emerges as a promising approach to understand the metabolic pathways associated with BPH, offering potential aid in early diagnosis. To investigate the metabolic profile of BPH patients compared with a control group for diagnosing BPH at different stages. A total of 62 individuals were selected and divided into two groups: 32 BPH (prostate volume > 40 mL) and 30 healthy individuals (prostate volume ≤ 40 mL and normal voiding patterns). Plasma samples were analyzed by LC-HRMS. Data were processed using unsupervised and supervised techniques. Self-organizing maps were further used to aid in the identification of potential biomarkers. Self-organizing maps revealed three distinct groups which expanded upon the existing groups indicated by the medical team. Discriminant analysis models showed good predictive ability and accuracy, providing a classification perspective of patients and expanding diagnostic possibilities for different health states. Integration of chemical data with clinical variables revealed meaningful correlations. Our results also suggest the presence of discriminatory metabolites related to inflammation and oxidation processes, clarifying the metabolic basis of BPH. Self-organizing maps proved their effectiveness in classifying groups of samples from BPH patients, revealing potential biomarkers that went undetected by conventional data analysis methods. This approach underscores metabolomics as a relevant tool in identifying hidden patterns and supporting the development of more robust diagnostic and prognostic models.
- Open Access
- 30 March 2024
- Published by MDPI AG in Metabolites
- Vol. 14 (4) , 195
COVID-19 and Comorbidities: What Has Been Unveiled by Metabolomics?
The COVID-19 pandemic has brought about diverse impacts on the global population. Individuals with comorbidities were more susceptible to the severe symptoms caused by the virus. Within the crisis scenario, metabolomics represents a potential area of science capable of providing relevant information for understanding the metabolic pathways associated with the intricate interaction between the viral disease and previous comorbidities. This work aims to provide a comprehensive description of the scientific production pertaining to metabolomics within the specific context of COVID-19 and comorbidities, while highlighting promising areas for exploration by those interested in the subject. In this review, we highlighted the studies of metabolomics that indicated a variety of metabolites associated with comorbidities and COVID-19. Furthermore, we observed that the understanding of the metabolic processes involved between comorbidities and COVID-19 is limited due to the urgent need to report disease outcomes in individuals with comorbidities. The overlap of two or more comorbidities associated with the severity of COVID-19 hinders the comprehension of the significance of each condition. Most identified studies are observational, with a restricted number of patients, due to challenges in sample collection amidst the emergent situation.
- 30 March 2024
- Published by MDPI AG in Metabolites
- Vol. 14 (4) , 195
Open AccessCOVID-19 and Comorbidities: What Has Been Unveiled by Metabolomics?
The COVID-19 pandemic has brought about diverse impacts on the global population. Individuals with comorbidities were more susceptible to the severe symptoms caused by the virus. Within the crisis scenario, metabolomics represents a potential area of science capable of providing relevant information for understanding the metabolic pathways associated with the intricate interaction between the viral disease and previous comorbidities. This work aims to provide a comprehensive description of the scientific production pertaining to metabolomics within the specific context of COVID-19 and comorbidities, while highlighting promising areas for exploration by those interested in the subject. In this review, we highlighted the studies of metabolomics that indicated a variety of metabolites associated with comorbidities and COVID-19. Furthermore, we observed that the understanding of the metabolic processes involved between comorbidities and COVID-19 is limited due to the urgent need to report disease outcomes in individuals with comorbidities. The overlap of two or more comorbidities associated with the severity of COVID-19 hinders the comprehension of the significance of each condition. Most identified studies are observational, with a restricted number of patients, due to challenges in sample collection amidst the emergent situation.